## Aurobindo Pharma Limited (AUROPHARMA) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Aurobindo Pharma Limited (AUROPHARMA) is a pharmaceutical company listed on the NSE (National Stock Exchange of India) since July 19, 2000.  It operates within the Pharmaceuticals & Biotechnology industry and holds a significant position in the Indian pharmaceutical market, known for its generic drug manufacturing and marketing.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,241.00       | Closed at ₹1,241.70; slightly down from the previous close.          |
| Percentage Change (PChange) | -1.09%          | Indicates a slight negative movement in the day's trading.           |
| Pre-Open Activity          | ₹1,254.80       |  Opened slightly higher than the previous close.                     |
| Week High                    | ₹1,592.00       | High reached on September 13, 2024.                               |
| Week Low                     | ₹958.50        | Low reached on February 14, 2024.                                 |
| VWAP                        | ₹1,261.43       | Volume Weighted Average Price for the day.                           |
| Sector PE                   | 19.88           | Price-to-Earnings ratio for the sector (NIFTY MIDCAP 50).           |
| Symbol PE                   | 20.25           | Price-to-Earnings ratio for AUROPHARMA.                             |
| Delivery Percentage         | 57.26%          |  Significant portion of traded volume was delivered.                |
| Market Depth                | Low              | Order book data shows low market depth (total buy/sell quantity = 0). This suggests limited liquidity.|


**3. Financial Performance:**

The following table summarizes Aurobindo Pharma's financial performance over the past five quarters.  Note that the data shows a consistent profit after tax and positive EPS, despite some fluctuations in revenue and expenses.  Further analysis of the provided financial statements is needed to calculate key financial ratios like Return on Equity (ROE), Debt-to-Equity ratio, etc. for a more comprehensive assessment.

| Quarter Ending      | Revenue (₹ in millions) | Expenses (₹ in millions) | Profit After Tax (₹ in millions) | Diluted EPS (₹) |
|----------------------|--------------------------|--------------------------|---------------------------------|-----------------|
| 30-Sep-2024          | 294,725                  | 222,350                  | 53,753                             | 9.21            |
| 30-Jun-2024          | 252,541                  | 207,917                  | 32,904                             | 5.62            |
| 31-Mar-2024          | 301,700                  | 223,712                  | 57,867                             | 9.88            |
| 31-Dec-2023          | 302,316                  | 233,594                  | 62,378                             | 10.65           |
| 30-Sep-2023          | 273,584                  | 222,606                  | 41,574                             | 6.48            |


**4. Corporate Actions and Announcements:**

Aurobindo Pharma has undertaken several corporate actions recently, including interim dividends and an AGM.  A recent buyback offer was also announced.  The numerous press releases and general updates suggest active communication with investors.  However, the specifics of these announcements (e.g., buyback details) require further investigation using the provided links to XBRL and other attachments.

**5. Shareholding Patterns:**

The promoter holding has remained relatively stable around 51.8% over the past year, indicating strong management confidence.

| Quarter Ending | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|-----------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023     | 51.83                        | 48.17      | 0.00                           | 100.00    |
| 31-Dec-2023     | 51.83                        | 48.17      | 0.00                           | 100.00    |
| 31-Mar-2024     | 51.83                        | 48.17      | 0.00                           | 100.00    |
| 30-Jun-2024     | 51.80                        | 48.20      | 0.00                           | 100.00    |
| 30-Sep-2024     | 51.82                        | 48.18      | 0.00                           | 100.00    |


**6. Volatility and Risk Assessment:**

The stock has shown significant volatility over the past year, as evidenced by the difference between the week high and week low.  The CM Annual Volatility of 32.67% further confirms this.  The low market depth adds to the risk profile, suggesting potential for sharp price swings.  The risk-reward profile needs further evaluation based on the investor's risk tolerance and expected returns.

**7. Advantages of Buying the Stock:**

* Consistent profitability and positive EPS over the past five quarters.
* Relatively stable promoter holding.
* Regular dividend payouts.
* Established presence in the pharmaceutical sector.

**8. Disadvantages and Risks:**

* High volatility and significant price swings.
* Low market depth, implying low liquidity.
* Dependence on the pharmaceutical sector, which is susceptible to regulatory changes and competition.
* The recent slump sale of API business units might impact future revenue streams.  Further analysis of the financial statements is needed to assess the impact.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The recent price decline and low market depth suggest caution.  Waiting for clearer price momentum is advisable.

* **Medium-term (3 to 12 months): Hold.**  The company's consistent profitability and stable promoter holding are positive factors. However, volatility remains a concern.  Monitoring financial performance and industry trends is crucial.

* **Long-term (1 year and beyond): Hold/Buy (with caution).**  Aurobindo Pharma's fundamentals are relatively strong, and its position in the growing pharmaceutical sector offers long-term potential.  However, investors should carefully assess their risk tolerance given the stock's volatility.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* Financial Health: 7/10 (Consistent profitability, but needs further ratio analysis)
* Market Performance: 5/10 (Volatility and recent price decline)
* Volatility and Risk: 4/10 (High volatility, low market depth)
* Corporate Actions & Governance: 8/10 (Regular dividends, active communication, but buyback details need further investigation)
* Shareholding Patterns: 8/10 (Stable promoter holding)

**Analysis Score (out of 10): 8/10**

* Completeness and Data Utilization: 9/10 (Most data used effectively)
* Accuracy and Clarity: 8/10 (Analysis is clear, but some aspects require deeper investigation)
* Professional Formatting: 9/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

Aurobindo Pharma presents a mixed investment picture. While the company demonstrates consistent profitability and a stable promoter base, its high volatility and low market depth pose significant risks.  Therefore, a cautious approach is recommended.  For short-term and medium-term horizons, a "Hold" strategy is suggested, pending further clarification on recent corporate actions and market conditions.  For long-term investors with a higher risk tolerance, a "Hold/Buy (with caution)" recommendation is given, contingent on continuous monitoring of the company's financial performance and industry trends.  Further investigation into the provided links for detailed financial statements and corporate action specifics is strongly recommended before making any investment decisions.
